JPWO2019239216A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019239216A5 JPWO2019239216A5 JP2020568967A JP2020568967A JPWO2019239216A5 JP WO2019239216 A5 JPWO2019239216 A5 JP WO2019239216A5 JP 2020568967 A JP2020568967 A JP 2020568967A JP 2020568967 A JP2020568967 A JP 2020568967A JP WO2019239216 A5 JPWO2019239216 A5 JP WO2019239216A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- sample
- preparation
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 claims description 78
- 239000000523 sample Substances 0.000 claims description 61
- 230000003612 virological Effects 0.000 claims description 53
- 241000700605 Viruses Species 0.000 claims description 51
- 238000002360 preparation method Methods 0.000 claims description 40
- 108020004999 Messenger RNA Proteins 0.000 claims description 24
- 229920002106 messenger RNA Polymers 0.000 claims description 24
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 23
- 150000007523 nucleic acids Chemical group 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007172 antigens Proteins 0.000 claims description 22
- 102000038129 antigens Human genes 0.000 claims description 22
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 claims description 19
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 19
- 230000004936 stimulating Effects 0.000 claims description 18
- 241000701161 unidentified adenovirus Species 0.000 claims description 16
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 10
- 229920002676 Complementary DNA Polymers 0.000 claims description 10
- 238000004166 bioassay Methods 0.000 claims description 10
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 238000003757 reverse transcription PCR Methods 0.000 claims description 10
- 101700048906 EBNA1 Proteins 0.000 claims description 9
- 238000009396 hybridization Methods 0.000 claims description 8
- 101700052293 ebr Proteins 0.000 claims description 7
- 230000003362 replicative Effects 0.000 claims description 7
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- CDRPUGZCRXZLFL-UHFFFAOYSA-N Piceatannol Chemical compound OC1=CC(O)=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-UHFFFAOYSA-N 0.000 claims description 4
- 101700006644 lmp-1 Proteins 0.000 claims description 4
- 230000001225 therapeutic Effects 0.000 claims description 4
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims description 3
- 210000003719 B-Lymphocytes Anatomy 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 3
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 3
- 230000001678 irradiating Effects 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684277P | 2018-06-13 | 2018-06-13 | |
| US62/684,277 | 2018-06-13 | ||
| PCT/IB2019/000811 WO2019239216A2 (fr) | 2018-06-13 | 2019-06-12 | Dosage de détection virale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021526826A JP2021526826A (ja) | 2021-10-11 |
| JPWO2019239216A5 true JPWO2019239216A5 (fr) | 2022-06-17 |
Family
ID=68842951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568967A Pending JP2021526826A (ja) | 2018-06-13 | 2019-06-12 | ウイルス検出アッセイ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230151438A1 (fr) |
| EP (1) | EP3807423A4 (fr) |
| JP (1) | JP2021526826A (fr) |
| AU (1) | AU2019286345A1 (fr) |
| CA (1) | CA3103367A1 (fr) |
| WO (1) | WO2019239216A2 (fr) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19709186C2 (de) * | 1997-03-06 | 1999-10-14 | Medigene Ag | Filtrationsverfahren zur Trennung von Viren |
| CA2393844A1 (fr) * | 1999-12-14 | 2001-06-21 | Genovo, Inc. | Methodes et compositions destinees a la fabrication d'adenovirus incompetents pour la replication |
| JP2008501360A (ja) * | 2004-06-11 | 2008-01-24 | カソリック ユニバーシティー インダストリー アカデミー コオペレーション ファウンデーション | ＣＥＡ−特異的な細胞毒性Ｔ細胞を生成する組み換えアデノウイルスＡｄＶＣＥＡで形質導入された樹枝状細胞、及びこれを含むワクチン並びに薬剤学的組成物 |
| RU2573912C2 (ru) * | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения |
| WO2011028531A1 (fr) * | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Génération de lignées de ctl avec une spécificité à l'encontre de multiples antigènes tumoraux ou de multiples virus |
| AU2011204405B2 (en) * | 2010-01-05 | 2015-06-18 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
| US10238734B2 (en) * | 2010-03-23 | 2019-03-26 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| WO2012089240A1 (fr) * | 2010-12-28 | 2012-07-05 | Qiagen Hamburg Gmbh | Sonde oligonucléotidique pour la détection d'un adénovirus |
| WO2013088114A1 (fr) * | 2011-12-12 | 2013-06-20 | Cell Medica Limited | Procédé de propagation de cellules t |
| SI3016512T1 (sl) * | 2013-07-05 | 2020-07-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Topni CD33 za zdravljenje mielodisplastičnih sindromov (MDS) |
| JP7136701B2 (ja) * | 2016-05-25 | 2022-09-13 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 同種異系ｔ細胞を用いた自己免疫疾患の処置方法 |
-
2019
- 2019-06-12 EP EP19819276.7A patent/EP3807423A4/fr active Pending
- 2019-06-12 JP JP2020568967A patent/JP2021526826A/ja active Pending
- 2019-06-12 WO PCT/IB2019/000811 patent/WO2019239216A2/fr unknown
- 2019-06-12 US US17/251,393 patent/US20230151438A1/en active Pending
- 2019-06-12 AU AU2019286345A patent/AU2019286345A1/en active Pending
- 2019-06-12 CA CA3103367A patent/CA3103367A1/fr active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6816031B2 (ja) | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 | |
| JP6971492B2 (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| Salvato et al. | Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence | |
| KR102663972B1 (ko) | 예비-면역화 단계가 없는 hiv 면역요법 | |
| Hamilton-Easton et al. | Virus-specific antigen presentation by different subsets of cells from lung and mediastinal lymph node tissues of influenza virus-infected mice | |
| WO2020224395A1 (fr) | Sonde, paire d'amorces, kit de pcr quantitative fluorescente et procédé de détection de lentivirus réplicatif | |
| US20070196389A1 (en) | Viral gene products and methods for vaccination to prevent viral associated diseases | |
| JP2021511802A (ja) | 複製可能ウイルスの存在または非存在を評価するための方法および試薬 | |
| WO2020224394A1 (fr) | Sonde fluorescente, paire d'amorces, kit de pcr quantitative fluorescente et procédé de détection pour la détection de lentivirus | |
| Sakaguchi et al. | In vitro host range of feline morbillivirus | |
| Mizuno et al. | Crossreactivity of antibodies to canine CD25 and Foxp3 and identification of canine CD4+ CD25+ Foxp3+ cells in canine peripheral blood | |
| US20220220175A1 (en) | Novel cancer antigens and methods | |
| Badenhoop et al. | IDDM patients neither show humoral reactivities against endogenous retroviral envelope protein nor do they differ in retroviral mRNA expression from healthy relatives or normal individuals. | |
| Ströhle et al. | A new mumps virus lineage found in the 1995 mumps outbreak in western Switzerland identified by nucleotide sequence analysis of the SH gene | |
| JP2021519069A (ja) | 遺伝子改変リンパ球の製造方法 | |
| Eo et al. | Plasmid DNA encoding CCR7 ligands compensate for dysfunctional CD8+ T cell responses by effects on dendritic cells | |
| KR20220034040A (ko) | 신규한 암 항원 및 방법 | |
| Romanutti et al. | Virus isolation and full-length genome sequencing of a representative canine distemper virus wild type strain of the South America 2 clade | |
| KR20210080372A (ko) | 신규의 암 항원 및 방법 | |
| JPWO2019239216A5 (fr) | ||
| EP4395809A1 (fr) | Vecteurs de hcmv recombinants et leurs utilisations | |
| Ponniah et al. | Selective response of gamma delta T-cell hybridomas to orthomyxovirus-infected cells | |
| CN113248577B (zh) | 一种以腺病毒为载体的冠状病毒疫苗及其制备方法 | |
| AKARI et al. | Simian T cell leukemia virus type I-induced malignant adult T cell leukemia-like disease in a naturally infected African green monkey: implication of CD8+ T cell leukemia | |
| US20230151438A1 (en) | Viral detection assay |